What happens when you stop GLP-1 medicines? Weight regain explained
Medically reviewed by Dr. Om J Lakhani on 18 Oct 2026 · Updated 18 Oct 2026
Short answer
In clinical trials, people who stopped semaglutide or tirzepatide regained a large part of the weight they had lost, about two-thirds within a year in one semaglutide study, and the improvements in sugar and blood pressure faded too. This happens because the body actively defends its higher weight by turning hunger back up, not because of a lack of willpower. For this reason doctors usually plan these medicines as long-term treatment, and any change or stop is best planned together with your doctor.
One of the first questions people ask before starting a weight-loss injection is: “Will I have to take it forever?” The honest answer is that for many people, the benefits last only as long as the treatment does. This is not a failure of the medicine or of the person. It reflects the nature of obesity as a long-term condition. For background, read GLP-1 medicines in India.
What do the trials show after stopping?
Three well-known trials looked directly at this question.
STEP 1 extension (semaglutide). Adults with obesity took weekly semaglutide for 68 weeks and lost about 17 percent of their body weight on average. Then the medicine and the trial’s lifestyle support were stopped. One year later, they had regained about two-thirds of the weight they had lost. Improvements in blood pressure, cholesterol and blood sugar also moved back towards where they started.
STEP 4 (semaglutide). Everyone took semaglutide for 20 weeks and lost about 10 percent of their weight. Then half were switched, without knowing, to a dummy injection. Over the next 48 weeks, those who continued lost a further 8 percent or so, while those switched to placebo regained about 7 percent.
SURMOUNT-4 (tirzepatide). People took tirzepatide for 36 weeks and lost about 21 percent of their weight. When half were switched to placebo, they regained about 14 percent of their body weight over the next year, while those who continued lost a further 5 percent or so. Nearly nine in ten who stayed on tirzepatide kept most of their loss, compared with about one in six of those who stopped.
The message from all three is the same: continuing treatment maintains the benefit, and stopping usually reverses much of it.
Why does the weight come back?
When you lose weight, by any method, your body reacts as if it is in danger:
- Hunger rises. Hormones that drive appetite go up and fullness signals go down.
- Food becomes more rewarding. Cravings and “food noise” return.
- Energy use falls a little. A smaller body burns fewer calories, and the body becomes more efficient.
GLP-1 medicines hold these signals in check. When they are stopped, the brain’s appetite system returns to its old settings, while the body’s drive to regain is still active. Weight regain is therefore a biological response, not a moral failure. The same happens after diet-only weight loss, which is why most diets are hard to sustain.
Does stopping undo the health benefits?
Largely, yes, over time. In the STEP 1 extension, most heart and metabolic improvements faded as weight returned. People with type 2 diabetes often see their HbA1c rise after stopping. There is also emerging research suggesting that the heart-protective effects of these medicines may not last after they are stopped, although this is still being studied.
So do I have to take it for life?
Not necessarily, but you should plan as if it may be long term. Indian and international guidelines describe obesity as a chronic disease that usually needs ongoing treatment, much like blood pressure or diabetes. Your doctor will discuss:
- Continuing treatment for as long as it helps and is tolerated, which is the approach best supported by the trials.
- Finding the lowest strength that maintains your weight. Some doctors try this once weight has been stable for a while. Evidence for this approach is still limited, so it should be done under supervision and not on your own.
- What to do if cost or supply becomes a problem, including switching between options. In India, generic semaglutide has made long-term treatment more affordable since 2026.
What helps keep the weight off?
Whether you continue or stop, the habits you build during treatment matter:
- Strength training at least two to three times a week, to protect muscle and metabolism.
- Enough protein at each meal. Read protein and muscle on weight-loss medicines.
- Regular weighing and waist checks, so you notice regain early.
- Sleep and stress management.
- Regular follow-up with your doctor or dietitian, especially in the first year after any change.
People who leave treatment with stronger habits and better muscle tend to regain less, although most still regain some weight.
What if I have already stopped?
If you have stopped and the weight is returning, you are not alone, and it is not your fault. Talk to your doctor. Restarting treatment, trying a different medicine, or stepping up lifestyle support are all options. Starting again usually means beginning at a low strength, so do not simply restart at your old strength without advice.
What should you ask your doctor?
- Is this treatment planned as long term for me?
- If I want to reduce or stop, how should we do it?
- What is my plan to protect muscle and keep the weight off?
- How often should I be reviewed after a change?
Planning for the long term is a key part of obesity care. Read what is obesity to understand why, or book a consultation.
When to see an endocrinologist
- You want to stop because of side effects or cost, and have not yet spoken to your doctor
- Your sugar levels rise again after stopping, especially if you have type 2 diabetes
- Rapid weight regain with breathlessness, swelling or rising blood pressure
- Binge eating, loss of control around food or low mood after stopping
Chest pain, fainting, severe breathlessness or confusion: call 108 or 112, or go to the nearest emergency department.
Book In-Person / Online ConsultationWatch the video
References
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022 (PMID 35441470)
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024 (PMID 38078870)
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021 (PMID 33755728)
- Madhu SV et al. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025). Indian J Endocrinol Metab 2025 (PMID 40917319)
This page is general health information and does not replace a consultation with your own doctor. Please read our medical disclaimer.